Blurbs

Analysts’ Top Healthcare Picks: Prophase Labs (PRPH), Regulus (RGLS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Prophase Labs (PRPHResearch Report) and Regulus (RGLSResearch Report) with bullish sentiments.

Prophase Labs (PRPH)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Prophase Labs today and set a price target of $14.00. The company’s shares closed last Monday at $9.91.

According to TipRanks.com, Chen has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -12.2% and a 31.0% success rate. Chen covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, HTG Molecular Diagnostics, and EyePoint Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Prophase Labs with a $9.50 average price target.

See today’s best-performing stocks on TipRanks >>

Regulus (RGLS)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Regulus, with a price target of $2.00. The company’s shares closed last Monday at $0.26, close to its 52-week low of $0.16.

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -46.2% and a 8.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding AG, Oramed Pharmaceuticals, and Timber Pharmaceuticals.

Currently, the analyst consensus on Regulus is a Moderate Buy with an average price target of $2.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on PRPH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos